| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Meryem Ozlem Kutuk, Ekaterina Berdzenishvili, Gülen Güler Aks. Hiccups in an Adult Case with Schizophrenia due to Aripiprazole: A Case Report. Noro psikiyatri arsivi. vol 58. issue 1. 2021-04-03. PMID:33795958. |
hiccups in an adult case with schizophrenia due to aripiprazole: a case report. |
2021-04-03 |
2023-08-13 |
Not clear |
| Meryem Ozlem Kutuk, Ekaterina Berdzenishvili, Gülen Güler Aks. Hiccups in an Adult Case with Schizophrenia due to Aripiprazole: A Case Report. Noro psikiyatri arsivi. vol 58. issue 1. 2021-04-03. PMID:33795958. |
our case describes the activation of hiccups in a young male with schizophrenia while being treated with aripiprazole. |
2021-04-03 |
2023-08-13 |
Not clear |
| Roger W Sommi, Bhaskar Rege, Angela Wehr, Sejal Faldu, Yangchun Du, Peter J Weide. Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals. CNS spectrums. 2021-03-29. PMID:33267924. |
aripiprazole lauroxil (al) is a long-acting atypical antipsychotic approved for the treatment of schizophrenia in adults. |
2021-03-29 |
2023-08-13 |
Not clear |
| Dalibor Karlović, Ante Silić, Danijel Crnković, Vjekoslav Peit. Effects of aripiprazole long-acting injectable antipsychotic on hospitalization in recent-onset schizophrenia. Human psychopharmacology. vol 36. issue 2. 2021-03-22. PMID:33058260. |
effects of aripiprazole long-acting injectable antipsychotic on hospitalization in recent-onset schizophrenia. |
2021-03-22 |
2023-08-13 |
Not clear |
| Dalibor Karlović, Ante Silić, Danijel Crnković, Vjekoslav Peit. Effects of aripiprazole long-acting injectable antipsychotic on hospitalization in recent-onset schizophrenia. Human psychopharmacology. vol 36. issue 2. 2021-03-22. PMID:33058260. |
aripiprazole lai (alai) is the newest of all lai's available on the market, with limited data on its effects on hospitalization rates after first episode of schizophrenia. |
2021-03-22 |
2023-08-13 |
Not clear |
| Adrian Preda, Bryan B Shapir. A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert opinion on drug safety. vol 19. issue 12. 2021-03-17. PMID:33064050. |
a safety evaluation of aripiprazole in the treatment of schizophrenia. |
2021-03-17 |
2023-08-13 |
Not clear |
| Adrian Preda, Bryan B Shapir. A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert opinion on drug safety. vol 19. issue 12. 2021-03-17. PMID:33064050. |
aripiprazole is a third generation antipsychotic approved by the us food and drug administration (fda) for the treatment of schizophrenia. |
2021-03-17 |
2023-08-13 |
Not clear |
| Anna Dietrich-Muszalska, Joanna Kolodziejczyk-Czepas, Pawel Nowa. Comparative Study of the Effects of Atypical Antipsychotic Drugs on Plasma and Urine Biomarkers of Oxidative Stress in Schizophrenic Patients. Neuropsychiatric disease and treatment. vol 17. 2021-02-26. PMID:33628026. |
therefore, in the present study, we assessed the ability of six atypical ads (clozapine, olanzapine, quetiapine, risperidone, aripiprazole, and ziprasidone) used in schizophrenia treatment to modulate oxidative damage to different biomolecules such as lipids and proteins. |
2021-02-26 |
2023-08-13 |
Not clear |
| Michael M C Wong, Albert K K Chung, Timothy M H Yeung, David T W Wong, C K Lee, Eric Lai, Gloria F Y Chan, Gregory K L Mak, Jessica O Y Wong, Roger M K Ng, K L Tam, K Y Ma. Consensus statements on the clinical usage and characteristics of aripiprazole for Hong Kong. Internal medicine journal. vol 50 Suppl 3. 2021-02-25. PMID:32985093. |
aripiprazole, a dopamine partial agonist, is a second-generation anti-psychotic that is widely used for the treatment of schizophrenia and other psychotic disorders. |
2021-02-25 |
2023-08-13 |
Not clear |
| Vieri Piazzini, Elisa Landucci, Matteo Urru, Alberto Chiarugi, Domenico E Pellegrini-Giampietro, Anna Rita Bilia, Maria Camilla Bergonz. Enhanced dissolution, permeation and oral bioavailability of aripiprazole mixed micelles: In vitro and in vivo evaluation. International journal of pharmaceutics. vol 583. 2021-02-10. PMID:32334067. |
aripiprazole (arp) is an antipsychotic drug approved for the treatment of schizophrenia. |
2021-02-10 |
2023-08-13 |
Not clear |
| Ya-Wen Jen, Tzung-Jeng Hwang, Hung-Yu Chan, Ming H Hsieh, Chen-Chung Liu, Chih-Min Liu, Hai-Gwo Hwu, Ching-Hua Kuo, Yi-Ting Lin, Yi-Ling Chien, Wei J Che. Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms? BMC psychiatry. vol 20. issue 1. 2021-02-10. PMID:33228575. |
abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms? |
2021-02-10 |
2023-08-13 |
Not clear |
| Umit Haluk Yesilkaya, Yasin Hasan Balciogl. Adjunct Aripiprazole for Obsessive-Compulsive Symptoms Associated With Second-Generation Antipsychotics in 2 Patients With Schizophrenia: Anti-obsessional Efficacy of Partial Agonism. Journal of clinical psychopharmacology. vol 40. issue 4. 2021-02-05. PMID:32433255. |
adjunct aripiprazole for obsessive-compulsive symptoms associated with second-generation antipsychotics in 2 patients with schizophrenia: anti-obsessional efficacy of partial agonism. |
2021-02-05 |
2023-08-13 |
Not clear |
| Ziyi Lin, Jianwei Xua. Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China. Expert review of pharmacoeconomics & outcomes research. vol 20. issue 5. 2021-02-05. PMID:32757968. |
cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in china. |
2021-02-05 |
2023-08-13 |
Not clear |
| Mingming Zheng, Ran Bi, Yezhe Lin, Cuizhen Zhu, Daomin Zh. Case report of the treatment and experience of mental disorders due to chronic viral encephalitis. General psychiatry. vol 34. issue 1. 2021-02-02. PMID:33521557. |
we present a case of a 16-year-old male patient who was previously hospitalised and diagnosed with schizophrenia and treated with aripiprazole 15 mg/day but failed to respond. |
2021-02-02 |
2023-08-13 |
Not clear |
| Nakao Iwata, Ataru Inagaki, Hiromi Sano, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamad. Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan. Advances in therapy. vol 37. issue 7. 2021-02-01. PMID:32500455. |
treatment persistence between long-acting injectable versus orally administered aripiprazole among patients with schizophrenia in a real-world clinical setting in japan. |
2021-02-01 |
2023-08-13 |
Not clear |
| Nakao Iwata, Ataru Inagaki, Hiromi Sano, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamad. Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan. Advances in therapy. vol 37. issue 7. 2021-02-01. PMID:32500455. |
to evaluate whether aripiprazole long-acting injection (aripiprazole once-monthly, aom) can contribute to longer treatment persistence compared with daily orally administered aripiprazole (oa) in real-world clinical settings in japan, treatment persistence in patients with schizophrenia was compared between patients treated with aom and those with oa, using a claims database compiled by jmdc inc., tokyo, japan. |
2021-02-01 |
2023-08-13 |
Not clear |
| Emma K Towlson, Petra E Vértes, Ulrich Müller-Sedgwick, Sebastian E Ahner. Brain Networks Reveal the Effects of Antipsychotic Drugs on Schizophrenia Patients and Controls. Frontiers in psychiatry. vol 10. 2021-01-10. PMID:31572229. |
we construct networks representing 15 healthy individuals and 12 schizophrenia patients (males and females), all of whom are administered three drug treatments: i) a placebo; and two antipsychotic medications ii) aripiprazole and iii) sulpiride. |
2021-01-10 |
2023-08-13 |
human |
| Piotr Ratajczak, Krzysztof Kus, Patrycja Murawiecka, Iwona Słodzińska, Tomasz Zaprutko, Dorota Kopciuch, Anna Paczkowska, Elżbieta Nowakowsk. Memory deterioration based on the tobacco smoke exposure and methylazoxymethanol acetate administration vs. aripiprazole, olanzapine and enrichment environment conditions. Pharmacology, biochemistry, and behavior. vol 189. 2021-01-07. PMID:31954117. |
the aim of this study was to find whether spatial memory function impairment is found in methylazoxymethanol acetate treated rats (an animal model of schizophrenia) and whether aripiprazole (1.5 mg/kg) and olanzapine (0.5 mg/kg) modify these functions. |
2021-01-07 |
2023-08-13 |
rat |
| Chengcheng Pu, Bingjie Huang, Tianhang Zhou, Zhang Cheng, Yi Wang, Chuan Shi, Xin Y. Gender Differences in the First-Year Antipsychotic Treatment for Chinese First-Episode Schizophrenia. Neuropsychiatric disease and treatment. vol 16. 2020-12-31. PMID:33364771. |
to investigate the gender differences in the efficacy and side effects of three frequently used antipsychotic medicines (risperidone, olanzapine, aripiprazole) for patients with first-episode schizophrenia during the first year of treatment. |
2020-12-31 |
2023-08-13 |
Not clear |
| Daniel Schöttle, Wolfgang Janetzky, Daniel Luedecke, Elmar Beck, Christoph U Correll, Klaus Wiedeman. The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index. BMC psychiatry. vol 20. issue 1. 2020-12-21. PMID:32087718. |
in this non-interventional study, the functionality and well-being of patients with schizophrenia with aripiprazole once-monthly (aom) was evaluated under real-life conditions in a naturalistic population. |
2020-12-21 |
2023-08-13 |
Not clear |